Afatinib monotherapy was approved by the US FDA for the first-line treatment of patients with EGFR-mutant, metastatic non-small-cell lung cancer (NSCLC) in July 2013 (Dungo and Keating, 2013). Here, EGFR is linked to non-small cell lung carcinoma.